Literature DB >> 1360530

Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.

E Yukawa1, H Mine, S Higuchi, T Aoyama.   

Abstract

Routine clinical pharmacokinetic data collected from patients receiving digoxin have been analysed to evaluate the role of patient characteristics for estimating dosing regimens. The data were analysed using NONMEM, a computer program designed for population pharmacokinetic analysis that allows pooling of data. The pharmacokinetic model of digoxin was described using a one-compartment steady-state model. The effect of a variety of developmental and demographic factors on clearance was investigated. NONMEM estimates indicate that digoxin clearance was influenced by the demographic variables of age, total body weight, serum creatinine and sex. The interindividual variability in digoxin clearance was modelled with additive error with an estimated standard deviation of 46.15 L day-1 and the intraindividual variability, or residual error was 0.209 ng mL-1. The dosing method based on clearance values obtained by NONMEM analysis allowed the prediction of the steady-state concentration as a function of maintenance dose with acceptable error for therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360530     DOI: 10.1111/j.2042-7158.1992.tb05515.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  10 in total

Review 1.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

3.  Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.

Authors:  Miho Yukawa; Eiji Yukawa; Fumihiro Suematsu; Takako Takiguchi; Hirohito Ikeda; Hatsumi Aki; Masao Mimemoto
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

Review 4.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

5.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

Review 6.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 7.  The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs.

Authors:  Shanna C Trenaman; Susan K Bowles; Melissa K Andrew; Kerry Goralski
Journal:  Pharmacol Res Perspect       Date:  2021-05

8.  Sex and gender differences in polypharmacy in persons with dementia: A scoping review.

Authors:  Shanna C Trenaman; Megan Rideout; Melissa K Andrew
Journal:  SAGE Open Med       Date:  2019-04-22

Review 9.  The influence of sex on pharmacokinetics.

Authors:  Janice B Schwartz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

10.  Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients.

Authors:  Toshiaki Komatsu; Mami Morita; Futaba Miyaji; Takayuki Inomata; Junya Ako; Koichiro Atsuda
Journal:  J Pharm Health Care Sci       Date:  2015-09-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.